Therapeutic Strategies For Tay-Sachs Disease

Overview

Journal Front Pharmacol

Date 2022 Jul 22

PMID 35865957

Authors

Jaqueline A Picache

Wei Zheng

Catherine Z Chen

Affiliations

Soon will be listed here.

Abstract

Tay-Sachs disease (TSD) is an autosomal recessive disease that features progressive neurodegenerative presentations. It affects one in 100,000 live births. Currently, there is no approved therapy or cure. This review summarizes multiple drug development strategies for TSD, including enzyme replacement therapy, pharmaceutical chaperone therapy, substrate reduction therapy, gene therapy, and hematopoietic stem cell replacement therapy. and systems are described to assess the efficacy of the aforementioned therapeutic strategies. Furthermore, we discuss using MALDI mass spectrometry to perform a high throughput screen of compound libraries. This enables discovery of compounds that reduce GM2 and can lead to further development of a TSD therapy.

Citing Articles

Diagnosing Late-Onset Tay-Sachs Through Next Generation Sequencing and Functional Enzyme Testing: From Genes to Enzymes.

Tupil A, Rivlin W, McCombe P, Henderson R, Rodgers J, Vadlamudi L Neurol Genet. 2025; 10(6):e200205.

PMID: 39807213 PMC: 11727987. DOI: 10.1212/NXG.0000000000200205.

Precise template-free correction restores gene function in Tay-Sachs disease while reframing is ineffective.

Hung J, Brewer R, Elbakr L, Mollica A, Forguson G, Chan W Mol Ther Nucleic Acids. 2025; 36(1):102401.

PMID: 39759878 PMC: 11699244. DOI: 10.1016/j.omtn.2024.102401.

Simultaneous surgery for gastrostomy and laryngotracheal separation in a patient with Tay‒Sachs disease.

Moroto M, Daisuke U, Yodoi T, Nitta Y, Sugimoto Y, Chiyonobu T Hum Genome Var. 2024; 11(1):43.

PMID: 39609393 PMC: 11604916. DOI: 10.1038/s41439-024-00300-0.

Founder mutations and rare disease in the Arab world.

Marafi D Dis Model Mech. 2024; 17(6).

PMID: 38922202 PMC: 11225585. DOI: 10.1242/dmm.050715.

Evidence of Lysosomal β-Hexosaminidase Enzymatic Activity Associated with Extracellular Vesicles: Potential Applications for the Correction of Sandhoff Disease.

Calzoni E, Cerrotti G, Sagini K, Delo F, Buratta S, Pellegrino R J Funct Biomater. 2024; 15(6).

PMID: 38921527 PMC: 11204914. DOI: 10.3390/jfb15060153.

References

Torres P, Zeng B, Porter B, Alroy J, Horak F, Horak J . Tay-Sachs disease in Jacob sheep. Mol Genet Metab. 2010; 101(4):357-63. DOI: 10.1016/j.ymgme.2010.08.006. View

Goina E, Peruzzo P, Bembi B, Dardis A, Buratti E . Glycogen Reduction in Myotubes of Late-Onset Pompe Disease Patients Using Antisense Technology. Mol Ther. 2017; 25(9):2117-2128. PMC: 5589062. DOI: 10.1016/j.ymthe.2017.05.019. View

Haslam C, Hellicar J, Dunn A, Fuetterer A, Hardy N, Marshall P . The Evolution of MALDI-TOF Mass Spectrometry toward Ultra-High-Throughput Screening: 1536-Well Format and Beyond. J Biomol Screen. 2015; 21(2):176-86. DOI: 10.1177/1087057115608605. View

Bradbury A, Gray-Edwards H, Shirley J, McCurdy V, Colaco A, Randle A . Biomarkers for disease progression and AAV therapeutic efficacy in feline Sandhoff disease. Exp Neurol. 2014; 263:102-12. PMC: 4262540. DOI: 10.1016/j.expneurol.2014.09.020. View

Worgall S, Sondhi D, Hackett N, Kosofsky B, Kekatpure M, Neyzi N . Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther. 2008; 19(5):463-74. DOI: 10.1089/hum.2008.022. View

Jacobs J, Willemsen M, Groot-Loonen J, Wevers R, Hoogerbrugge P . Allogeneic BMT followed by substrate reduction therapy in a child with subacute Tay-Sachs disease. Bone Marrow Transplant. 2005; 36(10):925-6. DOI: 10.1038/sj.bmt.1705155. View

Marchetti M, Faggiano S, Mozzarelli A . Enzyme Replacement Therapy for Genetic Disorders Associated with Enzyme Deficiency. Curr Med Chem. 2021; 29(3):489-525. DOI: 10.2174/0929867328666210526144654. View

Mistri M, Tamhankar P, Sheth F, Sanghavi D, Kondurkar P, Patil S . Identification of novel mutations in HEXA gene in children affected with Tay Sachs disease from India. PLoS One. 2012; 7(6):e39122. PMC: 3377590. DOI: 10.1371/journal.pone.0039122. View

Narita A, Shirai K, Itamura S, Matsuda A, Ishihara A, Matsushita K . Ambroxol chaperone therapy for neuronopathic Gaucher disease: A pilot study. Ann Clin Transl Neurol. 2016; 3(3):200-15. PMC: 4774255. DOI: 10.1002/acn3.292. View

10.

Eng C, Guffon N, Wilcox W, Germain D, Lee P, Waldek S . Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med. 2001; 345(1):9-16. DOI: 10.1056/NEJM200107053450102. View

11.

Osher E, Fattal-Valevski A, Sagie L, Urshanski N, Sagiv N, Peleg L . Effect of cyclic, low dose pyrimethamine treatment in patients with Late Onset Tay Sachs: an open label, extended pilot study. Orphanet J Rare Dis. 2015; 10:45. PMC: 4404274. DOI: 10.1186/s13023-015-0260-7. View

12.

Tropak M, Bukovac S, Rigat B, Yonekawa S, Wakarchuk W, Mahuran D . A sensitive fluorescence-based assay for monitoring GM2 ganglioside hydrolysis in live patient cells and their lysates. Glycobiology. 2009; 20(3):356-65. PMC: 2896968. DOI: 10.1093/glycob/cwp183. View

13.

Smith B, Collins S, Conlon T, Mah C, Lawson L, Martin A . Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in Pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther. 2013; 24(6):630-40. PMC: 3689178. DOI: 10.1089/hum.2012.250. View

14.

Wang D, Tai P, Gao G . Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019; 18(5):358-378. PMC: 6927556. DOI: 10.1038/s41573-019-0012-9. View

15.

Klinge L, Straub V, Neudorf U, Voit T . Enzyme replacement therapy in classical infantile pompe disease: results of a ten-month follow-up study. Neuropediatrics. 2005; 36(1):6-11. DOI: 10.1055/s-2005-837543. View

16.

Sanchez-Fernandez E, Garcia Fernandez J, Ortiz Mellet C . Glycomimetic-based pharmacological chaperones for lysosomal storage disorders: lessons from Gaucher, GM1-gangliosidosis and Fabry diseases. Chem Commun (Camb). 2016; 52(32):5497-515. DOI: 10.1039/c6cc01564f. View

17.

Gleitz H, Liao A, Cook J, Rowlston S, Forte G, DSouza Z . Brain-targeted stem cell gene therapy corrects mucopolysaccharidosis type II via multiple mechanisms. EMBO Mol Med. 2018; 10(7). PMC: 6034129. DOI: 10.15252/emmm.201708730. View

18.

Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C . Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial. Hum Gene Ther. 2014; 25(6):506-16. DOI: 10.1089/hum.2013.238. View

19.

Stepien K, Lum S, Wraith J, Hendriksz C, Church H, Priestman D . Haematopoietic Stem Cell Transplantation Arrests the Progression of Neurodegenerative Disease in Late-Onset Tay-Sachs Disease. JIMD Rep. 2017; 41:17-23. PMC: 6122053. DOI: 10.1007/8904_2017_76. View

20.

Hall P, Minnich S, Teigen C, Raymond K . Diagnosing Lysosomal Storage Disorders: The GM2 Gangliosidoses. Curr Protoc Hum Genet. 2014; 83:17.16.1-8. DOI: 10.1002/0471142905.hg1716s83. View